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Summary. Background: Only limited data on the incidence of
venous thrombosis in diﬀerent types of malignancy are
available. Patients with adenocarcinoma are believed to have
the highest risk of developing venous thrombosis. Objec-
tives: To study the incidence of thrombosis in patients with
lung cancer, with an emphasis on the comparison between
adenocarcinoma and squamous cell carcinoma, we have
performed a cohort study of patients with non-small-cell lung
cancer. In addition the risk associatedwith treatment and extent
of disease was assessed. Patients/methods: A total of 537
patients with a ﬁrst diagnosis of lung carcinoma were included.
Patient and tumor characteristics as well as venous thrombotic
events were recorded from the medical records and from the
AnticoagulationClinic.Results: Thrombotic risk in lungcancer
patients was 20-fold higher than in the general population
(standardized morbidity ratio (SMR): 20.0 (14.6–27.4). In the
group of patients with squamous cell cancer we found 10
(10/258) cases (incidence: 21.2 per 1000 years) of venous
thrombosis whereas in the group of patients with adenocarcin-
oma 14 (14/133) cases (incidence: 66.7 per 1000 years) occured.
The crude adjusted hazard ratio was 3.1 (95%CI: 1.4–6.9). The
risk increasedduringchemotherapyandradiotherapyand in the
presence of metastases. Conclusions: The risk of venous
thrombosis in lung cancer patients is increased 20-fold com-
pared to the general population. Patients with adenocarcinoma
have a higher risk than patients squamous cell carcinoma.
During chemotherapy or radiotherapy and in the presence of
metastases the risk is even higher.
Keywords: adenocarcinoma, lung cancer, squamous cell car-
cinoma, venous thrombosis.
Introduction
Venous thrombosis has an incidence in the general population
of 1–3 in 1000 per year [1,2]. Risk factors for thrombosis have
been identiﬁed andmay be either genetic or acquired, or have a
combined origin [3]. Among the risk factors for venous
thrombosis, cancer is an important and well-established risk
factor, leading to a 2- to 4-fold increased risk [4,5]. Eighteen
per cent of cancer patients have been reported to die of
pulmonary embolism (PE) [6].
Several factors may contribute to venous thrombosis in
cancer patients, such as immobilization, surgery, procoagulant
factors produced by the tumor cells [7], endothelial damage
caused by chemotherapy or stimulation of endothelial cells to
produce procoagulant material [8]. Patients with adenocarci-
noma are believed to have the highest risk of developing venous
thrombosis during the course of their disease. In 1865 Armand
Trousseau described patients with thrombophlebitis saltans et
migrans as well as deep venous thrombosis (DVT) as a ﬁrst
symptom of gastric carcinoma. He concluded there exists a
particular condition of the blood which predisposes it to
spontaneous coagulation [9].
In 1938 Sproul [10] conducted a postmortem study and
suggested a relation between pancreatic cancer and venous
thrombosis. She found thrombosis in 20%of themost common
malignancies and in 56% of the pancreas carcinomas. This
relationship between pancreatic cancer and venous thrombosis
has been conﬁrmed in many postmortem studies [11–13].
Among malignancies presenting with venous thrombosis as a
ﬁrst clinicalmanifestation,prostate andcolorectal cancerare the
most commonly identiﬁed (50%of the total number of patients
with occult cancer) [14]. Also cancers of the pancreas, stomach
andbladderare frequently reported tocausevenous thrombosis,
in about 20–30%of the patientswith thesemalignancies [15,16].
Hence, because of the high frequency of adenocarcinomas in
patients with venous thrombosis it has become a widespread
belief that the risk of thrombosis is paramount in adenocarci-
nomas.
We searched for data in the literature that support this
belief, but found strikingly few papers on the incidence of
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symptomatic DVT in patients with different histological types
of cancer. To further investigate the concept that adenocar-
cinomas are associated with a higher risk for venous throm-
bosis, we investigated the incidence of venous thrombosis in a
patient group with non-small-cell lung cancer, in particular
with the two major histological types of cancer, squamous cell
carcinoma and adenocarcinoma. This enabled us to compare
patients with adenocarcinoma vs. patients with squamous cell
carcinoma in a patient group with tumors arising in the same
organ.
We performed a follow-up study in consecutive patients with
non-small-cell lung cancer treated in one center over a 10-year
period and estimated the effect of therapy and extent of disease
on the risk of venous thrombosis.
Methods
From the oncology registration database of the hospital, we
identiﬁed 678 consecutive patients who were admitted with
non-small-cell lung cancer to the Leiden University Medical
Center between January 1990 and December 2000. The
oncology registration database is a dedicated database of our
hospital, in which information on all patients diagnosed with
and admitted for cancer in our hospital, are registered. The
database has been set up in 1970 and is staffed by specialized
oncology data managers. Fifty-seven medical records could
not be traced. Fifty patients were not included because they
only brieﬂy visited the Leiden University Medical Center for
laser therapy and 34 patients were not included because they
had a diagnosis of lung cancer before 1990 or a primary
diagnosis of lung cancer could not be conﬁrmed. Five
hundred and thirty-seven patients with a ﬁrst diagnosis of
lung cancer established in the Leiden University Medical
Center or with a ﬁrst diagnosis within 2 months before
referral to Leiden University Medical Center were selected for
the analysis.
Fromthemedical recordswe recorded clinical characteristics,
such as demographic data, use of anticoagulants, treatment
(chemotherapy, radiotherapy, surgery). Chemotherapy usually
consisted of a combination therapy of various cytotoxic agents
including carboplatin, cisplatin, gemcitabine or taxotere. In
addition, tumor characteristics were recorded: the histological
or cytological classiﬁcation of the tumor and the extent of the
disease. For 391 patients the diagnosis of lung cancer was based
on histological examination, whereas in 131 cases only a
cytological diagnosiswas available. In 15 cases referred byother
hospitals no information was available whether the diagnosis
was based on histological or cytological analysis was available.
For the classiﬁcation of the extent of disease we used three
stages. Patients without lymph node spread were classiﬁed as
having only local tumor growth (any T, N0,M0). Patients with
tumor growth in regional lymph nodes were classiﬁed as local
regional tumor growth (any T, N +, M0), as well as patients
with unknown T and N, but with M0. The third group was
formed by the patients with distant metastases (any T, any N,
M +). Whenever a postoperative staging was known, this
staging was used. In 28 cases staging was not performed due to
lack of treatment options.
We ascertained the occurence of a venous thrombotic event
(VTE) since diagnosis of cancer either by examining the
medical records of the Leiden University Medical Center and
the records of the anticoagulation clinic of the region where
the patient was living, or by consulting the general practi-
tioner of the patient. In the Netherlands, anticoagulation
clinics monitor all patients receiving treatment with oral
anticoagulant therapy in a speciﬁc region. Outcome events
were DVT or PE, occurring after the ﬁrst diagnosis of lung
cancer. Diagnosis of venous thrombosis was made in the
Leiden University Medical Center or in a hospital near the
patients’ home.
Information on the date of death was obtained from the
medical records, the registration ofﬁces of the municipalities
where the patients lived or from their general practitioner.
Three patients whose medical records were not available at the
anticoagulation clinic or general practitioner were lost to follow
up resulting in a loss of 1.5 person-years.
Statistical analysis
We counted person-years of follow-up for each subject from
the date of ﬁrst contact until the date of a thrombotic event, the
date of death, or the end of the study period (31 December
2000), whichever occured ﬁrst. A total of 879 person-years
accrued with maximally 1.5 person-years lost to follow up
(0.2%). We computed the incidence rates by dividing the
number of thrombotic events by the number of person-years. A
standardizedmorbidity ratio was calculated using the incidence
rate of DVT of the leg and PE in the Dutch population of 1994
[17].
We used Cox proportional hazard regression to adjust for
age, sex and other putative confounding variables. For the
analysis of the effect of therapy we used a Cox proportional
hazard model with time-dependent covariates. We constructed
a model which compared therapy vs. no therapy:
hðt;XðtÞÞ ¼ h0ðtÞ exp½b1therapyðtÞ;
where therapy(t) is 1 when t > ¼ start date of therapy and
t < ¼ end date of therapy, 0 when t < start date of therapy
and when t > end date of therapy.
To investigate the effect of duration of therapy we set up an
extended Cox model with time-dependent variables which
allowed a cumulative increase in risk with the duration of
therapy:
hðt;XðtÞÞ ¼ h0ðtÞ exp½b1therapyðtÞ þ b2durationðtÞ;
where the therapy(t) 1 when t > ¼ start date of therapy and
t < ¼ end date of therapy, 0 when t < start date of therapy
and when t > end date of therapy; duration(t) ¼ amount of
days of therapy at each t.
The hazard ratio is then calculated per day as:
HR ¼ exp½b1therapyðtÞ þ b2durationðtÞ:
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This model was compared to the simpler model that
compared only therapy vs. no therapy. The addition of the
duration of therapy to this simpler model was assessed by
comparing the )2 ln likelihood of the two models. The
underlying assumptions for the Cox proportional hazard
model were tested by visual inspection of the log-log survival
curves for the time-independent variables. The relative risk
associated with surgery was analyzed by introducing a time-
dependent covariate in the model indicating the time of surgery
plus 1 month for the postoperative period, as an arbitrarily
chosen time-window of increased risk.
Effect modiﬁcation by extent of disease was assessed in a
subgroup of patients for whom data on the stage of disease
were available. We used a Cox proportional hazards model
with a time-dependent covariate to account for changes in stage
during the course of the disease.
Analysis of the difference between squamous cell carcinoma
and adenocarcinoma was performed in a subgroup of patients
of whom the diagnosis of lung cancer was based on histological
and not cytological examination of the tumor in order to
minimize the probability of misclassiﬁcation of diagnosis.
For the survival analysis of patients who develop a venous
thrombosis after diagnosis of lung cancer we used a Cox
proportional hazards model with the thombotic event as a
time-dependent covariate.
Results
Characteristics of the cohort of 537 patients are shown in
Table 1. The mean age of the patients was 65 years and their
median survival 0.9 years. We observed 39 events of DVT over
879 years of follow-up (Table 2) for an overall incidence of
DVT of the leg or PE of 44.4 per 1000 person-years (95% CI:
31.3–57.5). Based on age- and sex-speciﬁc incidence rates from
the general Dutch population, two cases (incidence 2.0 per 1000
person-years) were expected for a cohort of this age- and sex-
distribution. Adjusted for age and sex, thrombotic risk in lung
cancer patients was 20-fold higher than in the general
population (standardized morbidity ratio (SMR): 20.0 (14.6–
27.4). The median time from ﬁrst admittance for lung cancer
until development of the VTE was 5.3 months (range
0.0–56.4 months). The incidence of VTE in the ﬁrst 6 months
after the diagnosis of lung cancer was 112.9/1000 person-years
(95% CI: 69.8–166.1), i.e. 4-fold higher than in the subsequent
time period. Sixteen patients had a previous VTE in their
medical history, and of these three patients also developed a
VTE after the diagnosis of lung carcinoma (incidence 93.8 per
1000 person-years [95% CI: 17.7–231.3]). Among those
without a history of venous thrombosis, the incidence after
lungcancer diagnosis was 42.6/1000 person-years (95% CI:
28.7–56.6). Two patients had a VTE before the diagnosis of
lung cancer, which was the trigger to search for occult
malignancy. These two thrombotic events were not included
in the analysis.
Among 258 patients with a histological conﬁrmed squamous
cell carcinoma we found 10 VTEs. In the group of 133 patients
with a histological conﬁrmed adenocarcinoma 14 VTEs
occurred. The incidence of venous thrombosis for patients
with squamous cell carcinoma was 21.2 per 1000 person-years
(95% CI:10.1–36.2) and for patients with an adenocarcinoma
66.7 per 1000 person-years (95% CI: 36.2–106.2) resulting in a
lower venous thrombosis-free survival in patients with adeno-
carcinoma as compared to patients with squamous cell
carcinoma (Fig. 1). The risk was 3-fold increased for patients
with adenocarcinoma vs. patients with squamous cell carci-
noma (crude hazard ratio 3.1 [95% CI: 1.4–6.9]). In a
regression model we adjusted for age, sex, chemotherapy
and radiotherapy. This yielded a hazard ratio of 2.8 (95%
Table 1 Patient characteristics
Total group
Squamous cell carcinoma*
(n ¼ 258)
Adeno carcinoma*
(n ¼ 133)
Tumor types squamous cell carcinoma 311
adenocarcinoma 158
other non-small cell
carcinomas
68
Men:women 429 : 108 222 : 36 97 : 36
Mean age (range) 65 (29–94) 67 (38–94) 63 (29–84)
Extent of disease any T N0 M0 142 (26%)
any T N +M0 163 (30%)
any T any N M + 204 (38%)
no staging 28 (5%)
Therapy Surgery 188 (35%) 108 (42%) 51 (38%)
Chemotherapy 81 (15%) 25 (10%) 25 (19%)
Radiotherapy 300 (56%) 148 (57%) 69 (52%)
Anticoagulants during follow up > ½ year
for reasons other than VTE
70 (12%) 47 (18%) 12 (9%)
Second malignancy 64 (12%) 42 (16%) 10 (8%)
Median survival after
diagnosis (year) (range)
0.9 (0.0–11.4) 1.0 (0.0–11.4) 0.8 (0.0–10.7)
*Histological conﬁrmed diagnosis.
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CI: 1.2–6.4) for patients with adenocarcinoma vs. patients with
squamous cell carcinoma. Adjustment for all these variables
and for spread of disease led to a hazard ratio of 2.1 (95% CI:
0.9–4.9). The same analysis was performed including patients
of whom only a cytological diagnosis was available. The crude
hazard ratio as well as the adjusted hazard ratios were slightly
lower (crude hazard ratio: 2.4 [95% CI: 1.2–5.0]) than for
histological conﬁrmed cases, which means there probably was
somemisclassiﬁcation of diagnosis due to the lower accuracy of
cytologically made diagnoses.
Analysis of the effect of cancer therapy and extent of disease
was performed for the total group. In 13 out of the 25 patients
with venous thrombosis who received chemotherapy or
radiotherapy as treatment for lung cancer, the symptoms of
VTE arose during or within 4 weeks after ending their therapy,
resulting in an incidence during or within 1 month after
chemotherapy or radiotherapy, of 279.4 per 1000 person-years
(95% CI: 111.7–522.8) and 110.2 per 1000 person-years (95%
CI: 40.4–216.9), respectively. In a Cox proportional hazards
model we estimated the effect of chemotherapywhile taking the
duration of therapy into account. This model gave the best ﬁt
to the data when we considered this therapy to have a
prothrombotic effect to persist until 70 days in the post-therapy
stage. The coefﬁcients were for therapy(t)b1 ¼ 1.168 and for
duration(t)b2 ¼ 0.005, adjusted for age and sex. According to
our model the risk of venous thrombosis increases 3-fold when
chemotherapy is started (HR 3.2, 95% CI: 2.1–4.3) compared
to the time when no chemotherapy is given. With increasing
duration of chemotherapy, the risk increases even further. At
the median duration of 58 days the risk is increased 4-fold (HR
4.3, 95% CI: 3.4–5.2) (Table 3). Adjusting for stage of disease
only slightly reduced these relative risks. Similarly, we analyzed
the effect of radiotherapy in a Cox proportional hazards
model. We used the simpler model, as the model taking the
duration of radiotherapy into account did not lead to a better
ﬁt of the data. The risk for patients who had received
radiotherapy was increased (HR 2.1, 95% CI: 0.6–7.1)
compared to patients without radiotherapy. Surgery was not
identiﬁed as a risk factor (HR 0.9, 95%CI: 0.1–6.6). Adjusting
for stage of disease did not alter this relative risk (HR 1.3, 95%
CI: 0.2–10.1). One patient presented with venous thrombosis in
the postoperative stage, i.e. within 1 month after operation. All
surgery patients were receiving thrombosis prophylaxis accord-
ing to the protocol of the hospital.
We evaluated the effect of distant metastases in a Cox
proportional hazards model, adjusting for age, gender and
therapy. The risk for patients with loco regional tumor growth
was not increased compared to patients with only local tumor
growth (HR 1.2, 95% CI: 0.4–3.3, adjusted for age, sex and
therapy). Patients with distant metastases had a 6-fold
increased risk compared to patients with only local tumor
growth (HR 6.5, 95% CI: 2.6–16.5, adjusted for age, sex and
therapy). The incidence rate in the presence of distant
Table 2 Incidence of venous thrombosis in the total group of lung cancer
patients
DVT 17
PE 15
DVT +PE 7
Total 39
Person years of follow up 879
Incidence DVT/PE (per 1000 person-years) 44.4
squarnous cell
adenocarcinoma
survival in days
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Fig. 1. Cumulative proportion of venous thrombosis in patients with a
squamous cell carcinoma vs. patients with an adenocarcinoma.
Table 3 The risk of venous thrombosis during cancer therapy compared to time without receiving therapy
Crude HR
Adjusted for
age and sex
+ Adjusted for
stage of disease*
Chemotherapy no 1
start 4.2 (3.1–5.3) 3.2 (2.1–4.3) 2.9 (1.8–4.0)
58 days (median duration) 5.3 (4.4–6.2) 4.3 (3.4–5.2) 3.3 (2.4–4.2)
83 days (mean duration) 5.9 (5.1–6.7) 4.9 (4.1–5.7) 3.4 (2.5–4.3)
Radiotherapy no 1
yes 2.1 (0.6–7.3) 2.1 (0.6–7.1) 1.9 (0.5–6.3)
Surgery no 1
yes 0.9 (0.4–7.4) 0.9 (0.1–6.6) 1.3 (0.2–10.1)
*In subgroup of whom extent of disease was known.
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metastases was very high at 220.5 per 1000 person-years (95%
CI: 157.1–355.9).
Survival time till death of patients who developed a VTE
during the course of their disease was decreased compared to
the survival of patients who did not develop a VTE. At any
moment after a VTE the risk of dyingwas 3-fold increased (HR
3.1, 95% CI: 2.2–4.4, adjusted for age, sex, therapy and extent
of disease). For both patients with distantmetastasis at the start
of follow-up as well as for patients without distant metastasis at
the start of follow-up we found an increased risk of dying after
a venous thrombotic event (Table 4).
Discussion
This large cohort study of 537 lung cancer patients shows that
the incidence of venous thrombosis is 20-fold increased
compared to the general population at 44.4 per 1000 patient-
years. The incidence is increased 3-fold in patients with
adenocarcinoma compared to patients with squamous cell
carcinoma. After adjustment for age, sex, therapy and distant
metastasis the hazard ratio of an adenocarcinoma vs. squa-
mous cell carcinoma was 2.1.
Since Trousseau, attention has been focused on the high risk
of venous thrombosis associated with adenocarcinomas. We
indeed found a 3-fold increased risk of venous thrombosis for
patients with an adenocarcinoma compared to patients with a
squamous cell carcinoma. The difference in incidence could not
be explained by the difference in treatment. Patients with an
adenocarcinoma more frequently received chemotherapy, but
adjusting for therapy did not change the hazard ratio to a great
extent, nor did adjustment for the presence of distantmetastasis
change the hazard ratio substantially.
Only one cohort study previously, assessed the incidence of
venous thrombosis in lung cancer patients. This study con-
cerned 280patientswith lung cancer and reported results similar
to ours [18]. Three per cent of the patients with a squamous cell
carcinoma and 8% of the patients with an adenocarcinoma
developed a clotting disorder, which could also be types of
venous thrombosis other than DVT of the leg or PE.
Recent research has shown that carcinoma mucins can
activate platelets and generate microthrombi in mice, most
likely through interaction with leukocyte L-selectin and platelet
P-selectin because this pathology was markedly diminished in
P- or L-selectin deﬁcient mice. Heparin (which potentiates
antithrombin and blocks P- and L-selectin) ameliorated this
platelet aggregation whereas recombinant hirudin (inhibition
of thrombin) did not. Thus interaction of circulating carcinoma
mucins with leukocyte L-selectin and platelet P-selectin without
requiring accompanying thrombin generation is a probable
molecular explanation for the increased incidence of venous
thrombosis in patients with adenocarcinoma [19].
Although many studies have shown an increased risk of
thrombosis in cancer [4,20], few studies describe the absolute
risk as incidence rates of venous thrombosis for cancer patients.
In our study we found an incidence rate of 44.4 per 1000
person-years for lung cancer patients. This annual rate of over
4% is a 20-fold increase compared to the general population.
A cohort study of cancer patients using aMedicare database
[21] reported the highest cumulative incidence in patients with
cancer of the ovaries, brain tumors, pancreatic tumors and
lymphoma. This was followed by gastro-intestinal tumors,
leukemia and lung cancer. Lung cancer patients had a
cumulative incidence of 61 per 10 000 during the 183 days of
follow-up after initial diagnosis. We found 21 cases in the ﬁrst
half-year of follow up resulting in a approximately six times
higher cumulative incidence of VTE of 391 per 10 000. This
difference may be explained by the difference in veriﬁcation of
the thrombotic event. We veriﬁed the thrombotic event by
checking the medical records of the hospital and the antico-
agulation clinics, whereas veriﬁcation in theMedicare database
study was done by record linkage ofMedicare data which have
been shown to underreport hospitalizations by 10–27% [22].
Furthermore, we excluded all non-primary lung cancer whereas
these may have been included in the Medicare database study.
The incidence of venous thrombosis as observed in our
cohort of lung cancer patients may even be underestimated as
venous thrombosis causing sudden death at home, may not
have been diagnosed and registered in the medical records.
Our data also showed that the risk for venous thrombosis
continues to be increased for about 2 months after the
discontinuation of chemotherapy whereas radiotherapy did
not show this effect. Thus far the main mechanisms of
thrombogenesis ascribed to chemotherapeutic agents are:
release of procoagulants and cytokines from damaged tumor
cells, a toxic effect on vascular endothelium, the fall of naturally
occurring anticoagulants due to hepatotoxicity [8]. Radiother-
apy probably mainly has a thrombogenic effect by release of
procoagulants and cytokines from damaged tumor cells. The
cumulative damage of vascular endothelium and liver caused
by chemotherapy might take longer to recuperate and thus
cause an increased risk of venous thrombosis with increasing
duration of therapy. Chemotherapy and radiotherapy have
previously been shown to be associated with an increased risk
of VTE [4,23,24].
We did not ﬁnd an increased risk of venous thrombosis
related to surgery, which is likely to be due to adequate
prophylaxis given to all patients who underwent surgery.
In conclusion, our study shows a high incidence of venous
thrombosis in lung cancer patients with a much higher
incidence in patients with adenocarcinoma as compared to
patients with squamous cell carcinoma. Because the incidence
Table 4 Risk of dying after a venous thrombotic event in patients with or
without distant metastasis
Hazard ratio
(95% CI)*
no distant
metastasis
venous thrombosis no 1
yes 3.2 (1.6–6.2)
distant
metastasis
venous thrombosis no 1
yes 4.5 (2.8–7.3)
*Adjusted for age, sex and therapy.
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of venous thrombosis signiﬁcantly increases during chemo-
therapy or radiotherapy and in the presence of distant
metastases, and exceeds the incidence of major bleeding (54
per 1000 person-years [25] and 125 per 1000 person-years [26]),
prophylactic anticoagulant treatment during the period of
treatment or in the presence of distant metastases may be
warranted to prevent development of venous thrombosis and
related morbidity and mortality. We suggest this should be
studied further in clinical trials.
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